Evidence map›Paper›PMID 40949131›Full record

ArticleFrontiers in pharmacology2025

c-MYC mRNA destabilization inhibited lethal pancreatic cancer

Jigme P Dorji, Queenie Chen, Sandali G Perera, Fizza Aijaz, Petvy Li, Tanjina Sania, Hiroshi Matsui, Chidiebere U Awah

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jigme P Dorji *UTR Therapeutics Inc., New York, NY, United States.
Queenie Chen *UTR Therapeutics Inc., New York, NY, United States.
Sandali G PereraDepartment of Chemistry, Hunter College, City University of New York, New York, NY, United States.
Fizza AijazUTR Therapeutics Inc., New York, NY, United States.
Petvy LiUTR Therapeutics Inc., New York, NY, United States.
Tanjina SaniaUTR Therapeutics Inc., New York, NY, United States.
Hiroshi MatsuiDepartment of Chemistry, Hunter College, City University of New York, New York, NY, United States.
Chidiebere U AwahUTR Therapeutics Inc., New York, NY, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic ductal carcinoma is the most common and deadly form of pancreatic cancer, with an 11% survival rate. There is currently no cure. The first-line, mainstay therapy for pancreatic cancer is gemcitabine, capecitabine, or FOLFIRINOX. After 21 months, the chemoresistance begins, driven by the oncogenic c-MYC signal. This is a significant clinical and cancer biology challenge. The c-MYC oncogene has been shown to be overexpressed in primary (43.1%) and metastatic (31.6%) pancreatic cancers, respectively, and is the primary driver of the neoplastic changes and progression of pancreatic cancer metastasis. Here, we report the

Indexed as

3′UTRMYC1-18c-Mycneuroendocrine pancreatic cancerpancreatic cancerpancreatic ductal carcinomaPD-L1

Identifiers

PMID40949131
PMCPMC12426058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.